At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
Last year, the company's early-stage breast cancer detection test became the first such test to receive the Breakthrough Device Designation
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Highlights strong Vibegron results in older men & real-world prostate cancer insights
With standout ADC and t-cell engager response data across hard-to-treat cancers
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
New facility at Pusa Road expands advanced diagnostic, theranostics, and treatment-planning capabilities across oncology, cardiology, neurology, and nephrology
Pharma giant targets new standards of care
Strong limited rollout adoption across major hospital networks positions company for accelerated scale-up in interventional radiology
Each program will rely on partnerships between Novartis teams and local networks—including health authorities, community organizations and private sector groups
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
